B Stubbs1, D Vancampfort2,3,4, M De Hert2,3, A J Mitchell5. 1. Faculty of Education and Health, University of Greenwich, London, UK. 2. University Psychiatric Centre, KU Leuven, Kortenberg, Belgium. 3. Departement of Neurosciences, KU Leuven, Kortenberg, Belgium. 4. Department of Rehabilitation Sciences, KU Leuven, Kortenberg, Belgium. 5. Department of Psycho-Oncology, Leicestershire Partnership NHS Trust, University of Leicester, Leicester, UK.
Abstract
OBJECTIVE: To conduct a meta-analysis investigating the prevalence of type two diabetes mellitus (T2DM) in people with schizophrenia compared to controls. METHOD: Systematic review of electronic databases from inception till November 2014. Articles reporting the prevalence of T2DM in people with schizophrenia and healthy controls (without mental illness) were included. Two independent authors conducted searches and extracted data. A random effects relative risks (RR) meta-analysis was conducted. RESULTS: Twenty-five studies including 145,718 individuals with schizophrenia (22.5-54.4 years) and 4,343,407 controls were included. The prevalence of T2DM in people with schizophrenia was 9.5% (95% CI = 7.0-12.8, n = 145,718) and 10.75% (95% CI 7.44-14.5%, n = 2698) in studies capturing T2DM according to recognized criteria. The pooled RR across all studies was 1.82 (95% CI = 1.56-2.13; = 4,489,125). Subgroup analyses found a RR of 2.53 (95% CI = 1.68-3.799, n = 17,727) in studies ascertaining T2DM according to recognized criteria and RR 1.65 (95% CI = 1.34-2.03, n = 4,243,389) in studies relying on T2DM determined through medical records. CONCLUSION: People with schizophrenia are at least double the risk of developing T2DM according to recognized T2DM criteria. Proactive lifestyle and screening programmes should be given clinical priority.
OBJECTIVE: To conduct a meta-analysis investigating the prevalence of type two diabetes mellitus (T2DM) in people with schizophrenia compared to controls. METHOD: Systematic review of electronic databases from inception till November 2014. Articles reporting the prevalence of T2DM in people with schizophrenia and healthy controls (without mental illness) were included. Two independent authors conducted searches and extracted data. A random effects relative risks (RR) meta-analysis was conducted. RESULTS: Twenty-five studies including 145,718 individuals with schizophrenia (22.5-54.4 years) and 4,343,407 controls were included. The prevalence of T2DM in people with schizophrenia was 9.5% (95% CI = 7.0-12.8, n = 145,718) and 10.75% (95% CI 7.44-14.5%, n = 2698) in studies capturing T2DM according to recognized criteria. The pooled RR across all studies was 1.82 (95% CI = 1.56-2.13; = 4,489,125). Subgroup analyses found a RR of 2.53 (95% CI = 1.68-3.799, n = 17,727) in studies ascertaining T2DM according to recognized criteria and RR 1.65 (95% CI = 1.34-2.03, n = 4,243,389) in studies relying on T2DM determined through medical records. CONCLUSION:People with schizophrenia are at least double the risk of developing T2DM according to recognized T2DM criteria. Proactive lifestyle and screening programmes should be given clinical priority.
Authors: J Ruppert; D Hartung; M Westhoff-Bleck; J Herrmann; B Stubbs; J Cordes; T H C Krüger; R Lichtinghagen; K G Kahl Journal: Eur Arch Psychiatry Clin Neurosci Date: 2017-11-23 Impact factor: 5.270
Authors: Jessica M Brooks; John Blake; Jennifer Sánchez; Elias Mpofu; Jia-Rung Wu; Xiangli Chen; Jonathan Nauser; Brandi P Cotton; Stephen J Bartels Journal: Community Ment Health J Date: 2019-05-16
Authors: Davy Vancampfort; Christoph U Correll; Britta Galling; Michel Probst; Marc De Hert; Philip B Ward; Simon Rosenbaum; Fiona Gaughran; John Lally; Brendon Stubbs Journal: World Psychiatry Date: 2016-06 Impact factor: 49.548